Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2015-07-02 Proxy Solicitation & In…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
Proxy Solicitation & Information Statement 2015
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a letter from a law firm to the SEC's Office of Mergers and Acquisitions responding to comments on filings related to a reverse stock split and proxy statement. It references Schedule 13E-3 and Schedule 14A filings, which are related to merger and acquisition activities and proxy solicitations respectively. The content focuses on legal authority, shareholder impacts, and procedural details of the reverse stock split, which is a capital restructuring event. The document is not the proxy statement itself but a comment response letter addressing SEC staff comments on the proxy statement and related filings. This type of document is best classified under Proxy Solicitation & Information Statement (PSI) because it deals with proxy materials and shareholder voting information related to the reverse stock split proposal. It is not an announcement of a report (RPA), nor a full annual or quarterly report, nor a merger filing itself, but rather a regulatory correspondence about proxy materials. The document length and detail confirm it is not a brief announcement or certification (RNS). Therefore, the most appropriate classification is PSI with high confidence.
2015-07-02 English
Regulatory Filings 2015
Regulatory Filings
2015-07-01 English
Regulatory Filings 2015
Regulatory Filings
2015-07-01 English
PRER14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Preliminary Proxy Statement (PRER14A) filed with the SEC, related to the Annual Meeting of Shareholders scheduled for July 2015. It includes detailed information about proposals to be voted on, such as election of directors, amendments to stock incentive plans, ratification of auditors, and amendments to articles of incorporation. The document is clearly a solicitation of shareholder votes and provides information necessary for shareholders to make informed voting decisions. This matches the definition of a Proxy Solicitation & Information Statement (PSI). The document is not an announcement of voting results (DVA), nor is it a full annual report or earnings release. The length and content confirm it is the proxy statement itself, not just an announcement or notice. Therefore, the correct classification is PSI with high confidence.
2015-06-24 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC's Office of Mergers and Acquisitions responding to staff comments on a Preliminary Proxy Statement on Schedule 14A and Schedule 13E-3 filings. It discusses revisions to a reverse stock split proposal and regulatory compliance matters. The document is short (3704 characters) and is a correspondence related to regulatory filings rather than a full report or proxy statement itself. It does not contain financial data or detailed report content but is a regulatory communication addressing SEC comments. Therefore, it fits best under Regulatory Filings (RNS) as a response to SEC staff comments and amendments to filings.
2015-06-24 English
Regulatory Filings 2015
Regulatory Filings Classification · 90% confidence The provided document text appears to be an encoded or binary file content (e.g., base64 or uuencoded data) rather than readable text. There are no discernible keywords, regulatory references, form names, fiscal period dates, or document titles that indicate the nature of the filing. The document length is 15,000 characters, which is substantial, but without readable content or metadata indicating the filing type, it is impossible to classify it as a specific report or announcement. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS).
2015-06-15 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.